ATE389399T1 - Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum - Google Patents

Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum

Info

Publication number
ATE389399T1
ATE389399T1 AT04797529T AT04797529T ATE389399T1 AT E389399 T1 ATE389399 T1 AT E389399T1 AT 04797529 T AT04797529 T AT 04797529T AT 04797529 T AT04797529 T AT 04797529T AT E389399 T1 ATE389399 T1 AT E389399T1
Authority
AT
Austria
Prior art keywords
diuretic
amiloride
triamterin
valsartan
combinations
Prior art date
Application number
AT04797529T
Other languages
English (en)
Inventor
Daniel Vasella
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29725841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE389399(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE389399T1 publication Critical patent/ATE389399T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04797529T 2003-11-03 2004-11-02 Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum ATE389399T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0325605.4A GB0325605D0 (en) 2003-11-03 2003-11-03 Combination of organic compounds

Publications (1)

Publication Number Publication Date
ATE389399T1 true ATE389399T1 (de) 2008-04-15

Family

ID=29725841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797529T ATE389399T1 (de) 2003-11-03 2004-11-02 Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum

Country Status (16)

Country Link
US (2) US20070072848A1 (de)
EP (1) EP1682122B9 (de)
JP (1) JP2007509900A (de)
KR (1) KR20060097025A (de)
CN (1) CN1878548A (de)
AT (1) ATE389399T1 (de)
AU (1) AU2004290505B2 (de)
BR (1) BRPI0416154A (de)
CA (1) CA2544230A1 (de)
DE (1) DE602004012593T2 (de)
ES (1) ES2303958T3 (de)
GB (1) GB0325605D0 (de)
PL (1) PL1682122T3 (de)
PT (1) PT1682122E (de)
RU (1) RU2006119329A (de)
WO (1) WO2005049013A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
US20140107170A1 (en) 2011-05-06 2014-04-17 Miso Sabovic Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
CN102793703A (zh) * 2011-05-25 2012-11-28 苏州洪瑞医药科技有限公司 一种盐酸阿米洛利和环戊噻嗪的药物组合物及其制备方法
CN109475552B (zh) * 2016-08-09 2022-04-05 上海药苑生物科技有限公司 用于食欲控制和体重管理的方法和组合物
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
AU8026200A (en) * 1999-10-19 2001-04-30 Board Of Regents, The University Of Texas System Treatment of heart disease with cox-2 inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1353727A2 (de) * 2000-12-01 2003-10-22 Novartis AG Kombinationen eines angiotensinrezeptor-hemmers und eines antihypertensiven medikaments oder eines statins, zur behandlung sexueller funktionsstörungen
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
EP1682122B9 (de) 2009-04-08
AU2004290505A1 (en) 2005-06-02
PT1682122E (pt) 2008-06-18
US20070072848A1 (en) 2007-03-29
GB0325605D0 (en) 2003-12-10
BRPI0416154A (pt) 2007-01-09
AU2004290505B2 (en) 2007-09-20
WO2005049013A1 (en) 2005-06-02
EP1682122A1 (de) 2006-07-26
US20090036432A1 (en) 2009-02-05
CN1878548A (zh) 2006-12-13
RU2006119329A (ru) 2007-12-27
DE602004012593T2 (de) 2009-04-23
PL1682122T3 (pl) 2008-09-30
EP1682122B1 (de) 2008-03-19
DE602004012593D1 (de) 2008-04-30
CA2544230A1 (en) 2005-06-02
JP2007509900A (ja) 2007-04-19
ES2303958T3 (es) 2008-09-01
KR20060097025A (ko) 2006-09-13

Similar Documents

Publication Publication Date Title
UY27720A1 (es) Aroilpiridinonas monocíclicas,
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
EP2415760A3 (de) CCR-9-Antagonisten
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
UA96449C2 (en) Stable laquinimod preparations
IL218494A0 (en) Substituted imidazo ring systems , pharmaceutical compositions comprising them and their use in the manufacture of medicaments
PL374024A1 (en) Terphenyl derivatives, preparation thereof, compositions containing same
IL212477A0 (en) Biaryl heterocyclic compounds, methods of making the same, pharmaceutical compositions comprising them and their use in the preparation of medicaments
WO2001076574A3 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
BR0317555A (pt) Composições farmacêuticas de sertaconazol para uso vaginal
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
PA8649901A1 (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
IL164464A0 (en) Antagonists to mcp proteins, their preparation, pharmaceutical composition containing them, and their use
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
ATE389399T1 (de) Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
HRP20050713A2 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
IL173004A0 (en) Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments
DE60323138D1 (de) Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
AU2003281468A1 (en) P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1682122

Country of ref document: EP

RZN Patent revoked